-
-
-
-
-
-
-
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Xencor (XNCR) Misses Q1 EPS by 4c
-
-
-
-
-
-
-
Xencor (XNCR) Misses Q2 EPS by 25c, provides guidance
-
-
-
-
-
-
-
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
-
-
-
-
-
-
-
Xencor (XNCR) Misses Q1 EPS by 36c
-
-
-
-
-
-
-
Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
-
-
-
-
-
-
-
Xencor Reports First Quarter 2022 Financial Results
-
1,217,544 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

